Viewing Study NCT05577715



Ignite Creation Date: 2024-05-06 @ 6:10 PM
Last Modification Date: 2024-10-26 @ 2:43 PM
Study NCT ID: NCT05577715
Status: RECRUITING
Last Update Posted: 2023-07-18
First Post: 2022-10-10

Brief Title: A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer NSCLC Adenocarcinoma AC
Sponsor: Bristol-Myers Squibb
Organization: Bristol-Myers Squibb

Study Overview

Official Title: A Phase 2 Open-label Randomized Study of MORAb-202 Farletuzumab Ecteribulin a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants With Metastatic Non-Small Cell Lung Cancer NSCLC Adenocarcinoma AC After Progression on Prior Therapies
Status: RECRUITING
Status Verified Date: 2023-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of this study is to characterize the safety and tolerability of MORAb-202 and to assess the objective response rate in participants with previously treated metastatic NSCLC AC
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2022-000131-23 EUDRACT_NUMBER None None
MORAb-202-G000-203 OTHER Eisai Protocol Number None